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LETTERS TO THE EDITORWHYARE THE RESULTS
REPORTED FROM THIS
CENTER INCONSISTANT WITH
THE GENERAL EXPERIENCE
OF 4000 IMPLANTS AND
10 YEARS OF FOLLOW-UP?
To the Editor:
The article previously published in
the Journal1 presents a series of cases
of the Shelhigh 2000C (Shelhigh Inc,
Union, NJ) aortic valve conduit for
the Bentall procedure. Shelhigh Inc
appreciates Carrel and colleagues’1
study of the device and their apprecia-
tion for the device’s benefits to pa-
tients. Although Shelhigh Inc is
interested in getting fair clinical feed-
back on its products, I believe the arti-
cle was misleading.
Aspects of the article beg important
questions, and, in my view, their arti-
cle lacks clinical context and historical
accuracy. I’d like to offer your readers
(1) a clearer account of the company’s
communication with Berne regarding
the devices, particularly with regard
to surgical technique; (2) a wider clin-
ical perspective on the device; and (3)
questions that the article simply begs
for an answer.
Shelhigh Inc was not remiss in
the close surveillance of its prod-
ucts. Before this publication, the
company had not seen most of the
cases in the article. Carrel and col-
leagues did not mention that despite
requests by Shelhigh Inc, they never
submitted full case documentation.
Those reports were particularly
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the company wanted properly to re-
port an adverse event to Swiss
medics. If Carrel and colleagues
are positive that Shelhigh Inc’s feed-
back was inadequate, they should
have sent in more information from
which to adjust the clinical under-
standing of the product. Regrettably,
even this article fails to provide
a complete clinical picture.
Regardless, as Shelhigh Inc noted to
Carrel and colleagues in the discussion
of one case, bleeding at the suture line
at the time of operation does not yield
best results: A false aneurysm can oc-
cur. Shelhigh Inc admonished them to
make sure the anastomosis is com-
pletely ‘‘dry.’’ Pledgets are one solu-
tion; tighter suture ‘‘bites’’ are
another. The literature documents this
common issue and suggests various
solutions.
Problems associated with aortic re-
construction are mainly caused by the
laxity of aortic tissues involved by
dissection and the difficulties in ob-
taining sufficient mechanical strength
and hemostasis in the reconstruction.2
In the case of hematoma and false an-
eurysm, the company believes they
were likely caused by errors in tech-
nique. But that is only half of the so-
lution: the clinical issues presented
by the patient (eg, age, thickness of
the aorta, and preexisting disease of
the aorta). Shelhigh Inc products are
often used in sick cohorts of patients3
(eg, endocarditis, patients in whom
anticoagulation must be obviated),
and great surgical care must always
be part of the overall clinical
solution.
Looking further afield into the entire
body of 2000C clinical experience, the
article’s cases seem specific to the site.
On analyzing the clinical data from
more than 4000 implants of the con-
duit over 10 years, the reported ad-
verse event rate is 0.3%. These
events are mainly from endocarditis.
Carrel and colleagues’ accusation of
a device ‘‘dissolving’’ and tissue de-
generation or calcification were neverl of Thoracic and Cardiovascular Surgerreported, and they never sent Shelhigh
Inc an explant of dissolved tissue. But,
even if all of the cases mentioned in
their article were included in adverse
data, the event rate increases to
0.5%. This is a very low event rate
when compared with homograft and
synthetic aortic root replacement op-
tions (2%–7%).
At no point does Shelhigh Inc put
reputational risk ahead of patient
safety. I would like to inform readers
that that is precisely why Shelhigh
Inc refused to implement a Food and
Drug Administration (FDA)-sug-
gested recall: No empirical evidence
suggested anything was wrong with
the devices, and despite unfounded
FDA concerns, explanting functioning
devices would present more risk to pa-
tients than the devices themselves. If
the FDA had any evidence of sterility
or structural issues for the devices, a re-
call would have been mandated by the
agency, I assure you. Looking back,
the decision was the right one.
European authorities agreed with
this view. In late 2007, the 25 mem-
ber nations of the European Union
exonerated Shelhigh Inc and its de-
vices, stating it found none of
the FDA deficiencies alleged. And
rightly so—the FDA never substanti-
ated its claims. As the recent tomato/
salmonella scare in the United States
suggests, despite best intentions, gov-
ernment agencies can sometimes miss
the mark.
Finally, I believe the article begs
several questions, which I’d like to ask:
Why weren’t these cases all
reported to the company?
Why were no deaths reported to the
company?
Why were these issues specific to
the site?
Why do the authors publish on 7
cases, when they only have partial
data on 4 of them?
If the results were so negative, why
was the product used for several years
and also reimplanted in 2 patients?
Why weren’t the warnings regard-
ing technique heeded?y c Volume 137, Number 5 1293
per year), surgery of the thoracic aorta
accounts for approximately 15% of
the overall surgical volume. This is
due to the high prevalence of aortic
aneurysms in the region and a high
rate of referrals. We perform approxi-
mately 200 to 220 thoracic aortic pro-
cedures per year. We most recently
published our results after surgery on
the thoracic aorta, and these are consis-
tent with contemporary literature.2-4
All patients described in our article1
were operated on by 3 senior staff sur-
geons (T.C., F.E., J.S.), each of whom
has approximately 20 years experience
in the field. None of them were ever
faced with a pathology like the one ob-
served with the NR-2000C aortic tube
valved conduit.
As Dr Gabbay pointed out, a signifi-
cant percentage of these patients were
high risk: A few of them underwent re-
reading the Food and Drug Adminis-
tration (FDA) document: ‘‘Your firm’s
[Shelhigh] Medical Device Reporting
Procedure (Document No. 020047) is
deficient in that: (1) The procedure
lacks a standardized review process
for determining when an event meets
the criteria for submitting an MDR re-
port. (2) There are no procedures for
documentation and record-keeping re-
quirements to determine if information
was evaluated to determine if an event
was reportable and that all events and
subsequent information are submitted
within appropriate timeframes.’’5
Unlike Dr Gabbay, we were
shocked to learn about additional, re-
peated warning letters issued by the
FDA (April 26, 2000, December 14,
2005), because we were not informed
by the company about ongoing prob-
lems and at the time they were brought
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Annescis, mi fili, quantilla sapientia
mundus regatur?
[Do you not know, my son, how
little wisdom rules the world?]
We thank Dr Gabbay for his letter to
the editor regarding our recent article,
‘‘Deleterious Outcome of No-React-
Treated Stentless Valved Conduits after
Aortic Root Replacement: Why Were
Warnings Ignored?’’1 We understand
that Dr Gabbay is under considerable
pressure because he is not only chief
scientific officer of Shelhigh Inc
(Union, NJ) but also founder and there-
fore directly dependent on the eco-
nomic well-being of the company. We
believe it is human nature that Dr
Gabbay is biased in his perception of
the events surrounding the aortic con-
duit NR-2000C (Shelhigh Inc) and
other products. We, as representatives
of a medical institution, have no interest
in accusing Dr Gabbay, but we merely
worry about the outcome observed in
some of our patients after having used
products from Shelhigh Inc.
In our department within the Aca-
demic Center for Cardiac Surgery
Berne-Basel (1800 cardiac cases
peat surgery because of endocarditis.
We hesitated a long time to attribute
these catastrophic findings to the Shel-
high device, but as the picture became
more consistent, we were able to rule
out other causes of failure, including
surgical technique. Our suspicion that
something was wrong with the device
was emphasized by similar observa-
tions with other Shelhigh products (eg,
the bovine internal thoracic artery used
as peripheral bypass conduit or excep-
tionally as coronary bypass conduit).
We are concerned about the fact
that Dr Gabbay refuses to acknowl-
edge findings as demonstrated in our
article.1 We had several meetings
with Dr Gabbay but it was never pos-
sible to bring our concerns to the point.
The fact that Dr Gabbay talks about
salmonella and tomatoes when we re-
port on patients who may unexpect-
edly die during follow-up or on the
operating table supports our decision
to not further discuss these matters
with the company itself. We send all
explanted material to our in-house cer-
tified pathology and microbiology de-
partment. Although we had severe
concerns with the management of the
company after several visits in Union,
New Jersey, we were terrified after
to our attention, we had already im-
planted the NR-2000C in more than
100 patients. We assume that the ma-
jority of the readers of the Journal
would be as worried as we are to learn
about such a critical situation. Citation
of the FDA: ‘‘The environmental con-
trols and processes used to manufac-
ture and test devices within your
facility can compromise the sterility
and safety of these products, and there
is therefore a reasonable probability
that use of such products will cause se-
rious adverse health consequences or
death.’’6
We can assure Dr Gabbay and the
readership of the Journal that these
patients receive the closest and most
optimal follow-up possible. However,
we are unable within this short letter
to provide detailed in-hospital data
and follow-up on these patients with
more than 1500 single items per pa-
tient, including repeated imaging and
extensive laboratory work. Dr Gabbay
insists that the issue is site specific, and
indeed that was one of the reasons we
hesitated to issue a formal complaint.
We do think at this point that the cir-
cumstances of a high aortic caseload
together with an unusual follow-up of
almost 100% may have helped to
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